Loading publications…
The last 5 uploaded publications
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han (2016). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), pp. 56-66, DOI: 10.1016/s0140-6736(16)32453-9.
Article145 days agoSEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang (2014). SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 33(6), pp. 559-566, DOI: 10.1200/jco.2013.53.7746.
Article145 days agoBiology and significance of alpha‐fetoprotein in hepatocellular carcinoma
Peter R. Galle, Friedrich Foerster, Masatoshi Kudo, Stephen L. Chan, Josep M. Llovet, Shukui Qin, William R. Schelman, Sudhakar Chintharlapalli, Paolo Abada, Morris Sherman, Andrew X. Zhu (2019). Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma. Liver International, 39(12), pp. 2214-2229, DOI: 10.1111/liv.14223.
Article145 days agoLenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Josep M. Llovet, Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, Peter R. Galle, Shuichi Kaneko, Tim Meyer, Shukui Qin, Corina E. Dutcus, Erluo Chen, Leonid Dubrovsky, Andrew X. Zhu (2019). Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. Journal of Clinical Oncology, 37(15_suppl), pp. TPS4152-TPS4152, DOI: 10.1200/jco.2019.37.15_suppl.tps4152.
Article145 days agoA study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
Andrew X. Zhu, Peter R. Galle, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Yihuan Xu, Paolo Abada, Josep M. Llovet (2018). A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).. Journal of Clinical Oncology, 36(4_suppl), pp. TPS538-TPS538, DOI: 10.1200/jco.2018.36.4_suppl.tps538.
Article145 days ago